NY-DUFF-&-PHELPS
Duff & Phelps Corporation , the premier global valuation and corporate finance advisor, today announced publication of the 2014 Valuation Handbook-Guide to Cost of Capital. The new book and companion Risk Premium Calculator help finance professionals estimate the cost of capital, an essential input to assess the feasibility of every merger and acquisition transaction and other strategic investments.
Determining the appropriate cost of capital, or discount rate, can be one of the most challenging aspects of any valuation analysis, particularly in volatile markets or during periods of economic uncertainty. Duff & Phelps’ new resources provide the approaches and data needed to make reliable estimates of this critical valuation assumption.
“With approximately $1.6 trillion in cash on corporate balance sheets-and an uptick in M&A activity thus far in 2014-reliable cost of capital estimates are imperative to achieving successful financial returns,” said Roger Grabowski, Duff & Phelps Managing Director and co-author of Cost of Capital, Applications and Examples . “We are pleased to provide corporate finance professionals and valuation practitioners with a comprehensive, definitive resource to develop estimates of cost of capital.”
The 2014 Valuation Handbook-Guide to Cost of Capital incudes the Duff & Phelps long-standing Risk Premium Report along with all of the critical year-end data that was previously available in the now discontinued Ibbotson ® Stock, Bonds, Bills and Inflation (SBBI® ) Valuation Yearbook. The new book will be updated annually.
In addition to the new 2014 Valuation Handbook-Guide to Cost of Capital , related resources that are now available include:
- Risk Premium Calculator : web-based resource for calculating cost of equity for users of data published in the Valuation Handbook-Guide to Cost of Capital . The model enables users to enter 1 - 18 inputs. Based upon these data points, the calculator delivers an executive summary, detailed results and four cost of equity estimates. This valuable tool also delivers historical equity risk premiums and size premiums for 25 size ranked portfolios using 8 alternative measures of company size.
- Cost of Capital, Applications and Examples, 4th Ed. (Chinese translation, 2013): co-authored by Duff & Phelps Managing Director Roger Grabowski. This is the first edition to be translated in response to increased demand for cost of capital resources in Asia.
Resources soon to be made available include:
- Cost of Capital, Applications and Examples, 5th Ed. (Wiley, 2014): co-authored by Duff & Phelps Managing Director Roger Grabowski, the 5th edition of this definitive reference book is an indispensable resource for a broad audience of valuation practitioners, investment bankers, CFOs, CPAs and finance professionals. The 5th edition includes expert commentary on the calculation of cost of capital for purposes of financial reporting and tax valuation, transfer pricing, litigation support and mergers and acquisitions, and is expected to ship in April of 2014.
- In summer 2014, the American Bar Association will publish The Lawyer’s Guide to Cost of Capital, co-authored by Duff & Phelps Managing Director Roger Grabowski. This text is designed to simplify the theoretical discussions to aid attorneys in understanding cost of capital issues in disputes. The book also contains chapters that summarize the various courts’ views on cost of capital.
The 2014 Valuation Handbook-Guide to Cost of Capital is now available for purchase through Business Valuation Resources , ValuSource and the AICPA . The Risk Premium Calculator is available through Business Valuation Resources. Advance orders of Cost of Capital, Applications and Examples , 5th Ed. can be made through Wiley .
On April 22 at noon Eastern Time and 4:00 p.m. GMT, Duff & Phelps will host a webcast , Calculating Cost of Capital-Matching Risk and Return.
To learn more about Duff & Phelps’ valuation and cost of capital expertise, please visit www.duffandphelps.com/cost of capital.
About Duff & Phelps
Duff & Phelps is the premier global valuation and corporate finance advisor with expertise in complex valuation, dispute consulting, M&A and restructuring. The firm’s more than 1,000 employees serve a diverse range of clients from offices in North America, Europe and Asia. For more information, visit www.duffandphelps.com .
M&A advisory, capital raising and restructuring services in the United States are provided by Duff & Phelps Securities, LLC. Member FINRA/SIPC. Pagemill Partners is a Division of Duff & Phelps Securities, LLC. M&A advisory and capital raising services in the United Kingdom and Germany are provided by Duff & Phelps Securities Ltd., which is authorized and regulated by the Financial Conduct Authority.
Contact:
Media Relations
Sherri Saltzman, +1-973-775-8329
or
Perry
Street Communications
Jennifer Sanders, +1-212-741-0014
duffandphelps@perryst.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 13:00:00 CEST | Press release
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letterIf approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 13:00:00 CEST | Press release
Experts from Qualcomm, Viant Medical, and Thermo Fisher Scientific join Kinaxis and economic futurist Andrew Busch to share insights on navigating tariff volatility As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s comin
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum